Arachidonic Acid Pathway and Eicosanoids

Understanding the arachidonic acid pathway is critical for grasping how inflammation, pain, fever, and even blood clotting occur at a molecular level. This cascade converts a simple membrane component into powerful signaling molecules called eicosanoids, which drive both protective physiological responses and detrimental disease processes. For the MCAT and your future medical career, mastering this pathway explains the mechanism of action for some of the most common drugs in the world, from aspirin to asthma inhalers.

The Gateway: Mobilizing Arachidonic Acid

The story begins not with arachidonic acid itself, but with its storage form. Arachidonic acid, a 20-carbon polyunsaturated fatty acid, is esterified and stored within the phospholipid bilayer of cell membranes. It remains inert until a specific signal—such as tissue injury, hormonal stimulus, or an immune response—triggers its release. This is the job of the enzyme phospholipase A2 (PLA2).

Phospholipase A2 acts like a precise molecular scalpel. It hydrolyzes the sn-2 ester bond of membrane phospholipids, liberating free arachidonic acid into the cell's interior. Once released, this free fatty acid does not linger; it is rapidly acted upon by enzymatic pathways within seconds to minutes. The fate of the arachidonic acid, and thus the physiological effect, depends on which enzyme pathway takes the lead. This initial mobilization step is a major regulatory control point for the entire inflammatory cascade.

The Cyclooxygenase (COX) Pathway: Prostaglandins and Thromboxanes

The cyclooxygenase pathway is mediated by the COX enzyme, which exists in two primary isoforms: COX-1 and COX-2. COX-1 is constitutively active, meaning it is always producing eicosanoids for "housekeeping" functions. COX-2, in contrast, is predominantly induced during inflammation. Both isoforms perform two key reactions: first, they add molecular oxygen to arachidonic acid to form the unstable intermediate PGG2 (cyclooxygenase activity), and then they reduce it to PGH2 (peroxidase activity).

PGH2 is the central, unstable precursor that is then transformed by specific tissue enzymes into a family of potent compounds:

• Prostaglandins (e.g., PGE2, PGI2): These have diverse and often opposing effects. PGE2 is a major mediator of vasodilation, pain (by sensitizing nerve endings), and fever (by acting on the hypothalamus). Prostacyclin (PGI2), produced by vascular endothelium, is a potent vasodilator and inhibitor of platelet aggregation.
• Thromboxane A2 (TXA2): Produced primarily by platelets, TXA2 has the opposite effect of PGI2. It is a powerful promoter of platelet aggregation (clotting) and a vasoconstrictor. This balance between PGI2 and TXA2 is crucial for maintaining vascular homeostasis.

Consider a localized infection. Tissue macrophages release cytokines that induce COX-2 in nearby cells. The resulting prostaglandins cause local vasodilation (redness and heat), increase vascular permeability (swelling), and sensitize pain receptors—cardinal signs of inflammation designed to bring immune cells to the area.

The Lipoxygenase (LOX) Pathway: Leukotrienes and Beyond

While the COX pathway is dominant in many tissues, immune cells like neutrophils, eosinophils, and mast cells favor the lipoxygenase pathway. The key enzyme here is 5-lipoxygenase (5-LOX), often working with a co-protein called FLAP (5-LOX activating protein). 5-LOX adds molecular oxygen to arachidonic acid at the 5th carbon, producing the unstable intermediate 5-HPETE, which is then converted to Leukotriene A4 (LTA4).

LTA4 is another branch-point molecule, giving rise to two critical classes of compounds:

• Cysteinyl leukotrienes (LTC4, LTD4, LTE4): These are historically known as the "slow-reacting substance of anaphylaxis" (SRS-A). They are extremely potent agents causing bronchoconstriction, increased mucus secretion in the airways, and increased vascular permeability. They are primary mediators in allergic asthma and anaphylaxis.
• LTB4: This is a potent chemoattractant for neutrophils, drawing them to sites of inflammation.

A clinical vignette: During an asthma attack, allergens trigger mast cells in the lung to release arachidonic acid metabolites. The cysteinyl leukotrienes from the LOX pathway cause the bronchial smooth muscle to contract tightly (bronchoconstriction) and the airway linings to swell, leading to wheezing and shortness of breath.

Pharmacological Intervention: Stopping the Cascade

The clinical importance of this pathway is fully realized in its pharmacologic inhibition. Drugs target different steps to produce specific therapeutic effects.

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): This ubiquitous class, including ibuprofen, naproxen, and aspirin, works by inhibiting COX enzymes. By blocking COX, they prevent the synthesis of all downstream prostaglandins and thromboxanes. This reduces inflammation, pain, and fever. The difference between aspirin and other NSAIDs is often irreversible (aspirin) versus reversible inhibition. A key MCAT point is the side-effect profile: inhibiting constitutive COX-1 can reduce protective prostaglandins in the stomach lining, leading to gastric irritation, and can impair kidney function.

1. Corticosteroids (e.g., prednisone): These are far more broad-spectrum anti-inflammatory agents. They induce the synthesis of a protein called lipocortin, which inhibits phospholipase A2. By blocking PLA2 at the very top of the cascade, corticosteroids prevent the release of arachidonic acid altogether. This means they suppress the production of all eicosanoids—both COX and LOX products. This explains their potent effect but also their wider range of side effects, as they interfere with this fundamental pathway in nearly all cells.

1. Leukotriene Modifiers (e.g., montelukast): Used specifically for asthma and allergy, these drugs either inhibit 5-LOX (like zileuton) or block the cysteinyl leukotriene receptor. They provide targeted relief against the bronchoconstrictive effects of the LOX pathway without affecting the COX pathway.

Common Pitfalls

• Confusing COX-1 and COX-2 Roles: A common mistake is to label COX-1 as "bad" and COX-2 as "good." Remember, COX-1 is vital for homeostatic functions like gastric cytoprotection and normal kidney function. COX-2 is largely responsible for pathological inflammation and pain. Ideal drug design seeks to inhibit COX-2 selectively while sparing COX-1.
• Misattending the Source of Inflammation: Don't attribute all inflammation to prostaglandins. In conditions like acute asthma, the lipoxygenase pathway (leukotrienes) is the dominant driver of the pathological symptoms. Knowing which pathway is primary dictates the drug choice.
• Overlooking the TXA2/PGI2 Balance: In cardiovascular physiology, the equilibrium between platelet-derived TXA2 (pro-thrombotic) and endothelial-derived PGI2 (anti-thrombotic) is essential. Low-dose aspirin therapy works by irreversibly inhibiting platelet COX-1, reducing TXA2 production for the platelet's lifespan, thus favoring an anti-aggregatory state.
• Forgetting the Speed: Eicosanoids are not stored; they are synthesized de novo from membrane lipids and act locally as autocrine or paracrine signals. They are not circulating hormones like insulin. They have extremely short half-lives, measured in seconds to minutes.

Summary

• The arachidonic acid pathway is a central inflammatory cascade, initiated when phospholipase A2 releases arachidonic acid from membrane phospholipids.
• The cyclooxygenase (COX) pathway produces prostaglandins (mediators of vasodilation, pain, and fever) and thromboxane A2 (a promoter of platelet aggregation and vasoconstriction).
• The lipoxygenase (LOX) pathway produces leukotrienes, which are key mediators in asthma and allergies, causing potent bronchoconstriction and increased vascular permeability.
• NSAIDs (like ibuprofen) provide anti-inflammatory, analgesic, and antipyretic effects by inhibiting COX enzymes.
• Corticosteroids (like prednisone) have broader, more potent anti-inflammatory effects because they inhibit phospholipase A2, preventing the initial release of arachidonic acid and the production of all downstream eicosanoids.